Preventing cancer recurrence with novel antibody–drug conjugates
Presidential presentations in early breast cancer provide first evidence of ADCs rapidly moving into the curative setting across multiple cancer types
Peri-operative enfortumab vedotin plus pembrolizumab prolongs survival in muscle-invasive bladder cancer
In KEYNOTE-905/EV-303, the combination of an antibody–drug conjugate and immunotherapy showed statistically significant and clinically meaningful improvements in event-free survival and overall survival
Trastuzumab deruxtecan is moving to the curative setting in early HER2-positive breast cancer
Positive findings from the DESTINY-Breast05 and DESTINY-Breast11 trials suggest that a paradigm change in the treatment of high-risk patients may be imminent
Head and neck cancers: should research continue to invest in immunotherapy?
Despite growing disappointing results from clinical trials, focus should now turn to the design of studies to better reflect tumour heterogeneity
Is thymic health a novel tumour-agnostic biomarker?
Study findings reveal that good thymic health, based on an AI-derived algorithm, is associated with improved survival after immunotherapy in different tumour types
What is the clinical value of genomic profiling in rare cancers?
Early studies investigated the potential of genomic profiling, but prospective and comprehensive data are required to support wider implementation
Extensive-stage small-cell lung cancer: new approaches on the horizon?
Tarlatamab as first-line therapy and ceralasertib plus durvalumab as maintenance therapy have demonstrated potential efficacy and manageable tolerability
Local consolidative therapy combined with osimertinib improves progression-free survival in metastatic EGFR-mutant NSCLC
Results from the NorthStar trial highlight the potential for integrating local therapy with targeted agents to extend disease control in this setting
Long-term phase III data reinforce the benefits of CDK4/6 inhibitors in early breast cancer
Follow-up data at 7 and 5 years from monarchE and NATALEE provide reassurance of the sustained benefits of adjuvant CDK4/6 inhibitors in improving survival and reducing relapse
Is less more for patients with genitourinary cancers?
Study results support alternative treatment regimens in prostate and urothelial tumours, showing similar efficacy to standard care while reducing treatment burden